Cargando…
Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown
The best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of an effective vaccine. However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven sufficiently safe and efficient to warrant commercial de...
Autores principales: | Alami Chentoufi, Aziz, Kritzer, Elizabeth, Yu, David M., Nesburn, Anthony B., BenMohamed, Lbachir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324142/ https://www.ncbi.nlm.nih.gov/pubmed/22548113 http://dx.doi.org/10.1155/2012/187585 |
Ejemplares similares
-
Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections
por: Chentoufi, Aziz Alami, et al.
Publicado: (2012) -
Immunity to Ocular and Genital Herpes Simplex Viruses Infections
por: Chentoufi, Aziz Alami, et al.
Publicado: (2012) -
Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back
por: Chentoufi, Aziz A., et al.
Publicado: (2022) -
Linear and Branched Glyco-Lipopeptide Vaccines Follow Distinct Cross-Presentation Pathways and Generate Different Magnitudes of Antitumor Immunity
por: Renaudet, Olivier, et al.
Publicado: (2010) -
A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8(+) T cells and protects against herpes simplex virus type 2 challenge
por: Zhang, X, et al.
Publicado: (2009)